Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of two dose-escalation regimens of once-weekly semaglutide in type 2 diabetes previously treated with GLP-1 RAs
2019-004234-42Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Jan 2020; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-004234-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004234-42.